elarofiban has been researched along with nipecotic acid in 1 studies
| Studies (elarofiban) | Trials (elarofiban) | Recent Studies (post-2010) (elarofiban) | Studies (nipecotic acid) | Trials (nipecotic acid) | Recent Studies (post-2010) (nipecotic acid) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 308 | 0 | 43 |
| Protein | Taxonomy | elarofiban (IC50) | nipecotic acid (IC50) |
|---|---|---|---|
| Sodium- and chloride-dependent GABA transporter 1 | Homo sapiens (human) | 5.3367 | |
| Sodium- and chloride-dependent GABA transporter 1 | Mus musculus (house mouse) | 8.1516 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade-Gordon, P; Cohen, JH; Costanzo, MJ; Damiano, BP; Haertlein, BJ; Hecker, LR; Hoekstra, WJ; Hulshizer, BL; Kauffman, JA; Keane, P; Maryanoff, BE; McComsey, DF; Mitchell, JA; Scott, L; Shah, RD; Yabut, SC | 1 |
1 other study(ies) available for elarofiban and nipecotic acid
| Article | Year |
|---|---|
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Dogs; Magnetic Resonance Spectroscopy; Mass Spectrometry; Nipecotic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proline; Pyridines; Structure-Activity Relationship | 1999 |